Prima BioMed Ltd (PBMD) Receives Consensus Rating of “Strong Buy” from Analysts

Prima BioMed Ltd (NASDAQ:PBMD) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.

Analysts have set a 1 year consensus price objective of $7.00 for the company, according to Zacks. Zacks has also assigned Prima BioMed an industry rank of 111 out of 265 based on the ratings given to its competitors.

Separately, Maxim Group reaffirmed a “buy” rating and set a $7.00 target price on shares of Prima BioMed in a report on Thursday, November 9th.

An institutional investor recently bought a new position in Prima BioMed stock. Sabby Management LLC purchased a new stake in shares of Prima BioMed Ltd (NASDAQ:PBMD) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 962,835 shares of the biotechnology company’s stock, valued at approximately $1,993,000. Sabby Management LLC owned 4.08% of Prima BioMed at the end of the most recent quarter. Institutional investors own 4.38% of the company’s stock.

Shares of Prima BioMed (NASDAQ PBMD) traded down $0.07 during midday trading on Friday, hitting $1.73. The stock had a trading volume of 85,847 shares, compared to its average volume of 73,500. Prima BioMed has a twelve month low of $1.40 and a twelve month high of $3.26. The company has a debt-to-equity ratio of 0.22, a current ratio of 6.06 and a quick ratio of 6.06.

ILLEGAL ACTIVITY NOTICE: This report was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at

Prima BioMed Company Profile

Prima BioMed Ltd is a biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. It is also focused on development of immunotherapeutic products. The Company operates through Cancer Immunotherapy segment. Its core technologies are based on the Lymphocyte-activation gene 3 (LAG-3) immune control mechanism, which is involved in regulation of the T cell immune response.

Get a free copy of the Zacks research report on Prima BioMed (PBMD)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Prima BioMed Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prima BioMed Ltd and related companies with's FREE daily email newsletter.

Leave a Reply